T. Rowe Price Investment Management Inc. 13D and 13G filings for Ascendis Pharma A/S:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 1:28 pm Sale | 2024-09-30 | 13G | Ascendis Pharma A/S ASND | T. Rowe Price Investment Management Inc. | 1,765,042 2.900% | -2,224,788 (-55.76%) | Filing |
| 2024-02-14 10:04 am Purchase | 2023-12-31 | 13G | Ascendis Pharma A/S ASND | T. Rowe Price Investment Management Inc. | 3,989,830 6.900% | 3,989,830 (New Position) | Filing |